Campbell & Co Investment Adviser’s Arcutis Biotherapeutics ARQT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$743K	Buy	+31,544	New	+$805K	0.04%	610
2025 Q4	–	Sell	-39,879	Closed	-$752K	–	1123
2025 Q3	$752K	Buy	39,879 +23,730	+147%	+$374K	0.06%	543
2025 Q2	$226K	Sell	16,149 -59,050	-79%	-$828K	0.01%	1031
2025 Q1	$1.18M	Sell	75,199 -520	-0.7%	-$7.33K	0.09%	361
2024 Q4	$1.05M	Buy	75,719 +171	+0.2%	+$1.87K	0.08%	370
2024 Q3	$703K	Buy	75,548 +12,455	+20%	+$123K	0.05%	578
2024 Q2	$587K	Buy	+63,093	New	+$571K	0.05%	594

Other funds holding ARQT

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return